Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

962P Best practices and impact of multi-disciplinary teams on hepatocellular carcinoma treatment: Insights from a global effort

Autor: Azcue, P., Campos Partera, M.T., Vogel, A., Sapisochin, G., Digklia, A., Villadsen, G.E., Schnatwinkel, C., Kothari, M., Gallego-Llorente, M., Cui, Y.P., Flieswasser, T., Turner, L., Vereecken, W., Moucquot, A., Naqvi, H., Dellamonica, D.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S663-S663

846P Artificial intelligence-driven identification of onco-hematology patients who may develop severe COVID-19

Autor: Assaad, S., Blay, J-Y., Crochet, H., Heudel, P-E., Bouam, S., Revel, M-P., Chassagnon, G., Bigenwald, C., Albiges, L., André, F., Battistella, E., Teboul, O., Pescia, D., Bertrand, B., D'Amico-Gandia, E., Kandeil, W., Guillet, M., Remorino, A., Dellamonica, D., Paragios, N.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S551-S551

917P OPTIMA: Improve care for patients with prostate, breast, and lung cancer through artificial intelligence

Autor: N’Dow, J., Smith, E.J., Polychronopoulos, K., Cannon, A., Roobol, M., Auweter, S., Thomas, M., Kremer, A., De Meulder, B., Dellamonica, D., Alhambra, D.P., Asiimwe, A., Bussmann, M., Ji, X., Torremante, P., Keller, S., Kube, F., Krueger, H.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S966-S966

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

Autor: Raymond, E, Nicot, F., Morand-Joubert, A, Rodallec, D, Mourez, M, Beby-Defaux, D, Lambert-Niclot, P, Charpentier, E, Malvé, B., Le Guillou-Guillemette, A, Si-Mohamed, D, Avettand Fenoel, A, Roussel, A., Calvez, P, Saune, E, Rodriguez, M, Descamps, E, Izopet, E, Lagier, E, Roussel, C, Le Guillou-Guillemette, G, Alloui, A., Bettinger, D., Pallier, P, Fleury, Frédéric, Reigadas, R, Bellecave, P., Recordon-Pinson, P, Payan, P, Vallet, S., Vabret, A., Dina, D, Henquell, C., Mirand, A., Bouvier-Alias, A, de Rougemont, A, Dos Santos, D, Morand, P, Signori-Schmuck, A., Bocket, B, Rogez, R, Andre, A, Tardy, C, Trabaud, A, Tamalet, C., Delamare, D, Montes, B, SCHVOERER, Evelyne, Ferré, F., André-Garnier, E., Cottalorda, C, Guinard, G, Guiguon, A, Descamps, D., Brun-Vézinet, B, Charpentier, c, Visseaux, B, Peytavin, G., Krivine, A., Si-Mohamed, A, Avettand-Fenoel, Véronique, Marcelin, A, Calvez, C, Lambert-Niclot, L, Soulié, C., Wirden, M., Morand-Joubert, M, Delaugerre, D, Chaix, M, Amiel, A, Schneider, S., Giraudeau, G, Beby- Defaux, D, Brodard, B, Maillard, A., Plantier, P, Chaplain, C, Bourlet, B, Fafi-Kremer, F, Stoll-Keller, F., Schmit, P, Barth, B, Yerly, S, Poggi, P., Izopet, I, Raymond, R, Barin, B, Chaillon, A, Marque-Juillet, M, Roque-Afonso, A, Haïm-Boukobza, B, Flandre, P., Grudé, G, Assoumou, A, Costagliola, D, Allegre, A, Schmit, J, Chennebault, M, Bouchaud, B, Magy-Bertrand, B, Delfraissy, D, Dupon, D, Morlat, P, Neau, D, Ansart, A., Jaffuel, J, Verdon, R, Jacomet, C, Lévy, L, Dominguez, D, Chavanet, P., Piroth, P, Cabié, A., Leclercq, P, Ajana, A, Cheret, A, Weinbreck, P, Cotte, C, Poizot-Martin, P, Ravaud, R., Christian, B, Truchetet, F, Grandidier, G, Rey, R., May, M, Goehringer, G, Raffi, F., Dellamonica, D, Prazuck, P, Hocqueloux, L, Landman, R, Yazdanpanah, Y., Launay, L, WEISS, L, Viard, P, Katlama, C., Simon, A., Girard, G, Meynard, M, Molina, M, Pialoux, G, Hoen, B., Goeger-Sow, G, Lamaury, I, Beaucaire, G, Le Moal, G., Jaussaud, R., Rouger, C, Michelet, M., Borsa-Lebas, B, Caron, F, Khuong, A., Lucht, F., Rey, D., Calmy, A, Lafeuillade, A, Marchou, B, Delobel, D, Gras, G, Greder-Belan, A, Vittecoq, D, Teiche, E

Publikováno v: Clinical Infectious Diseases
Clinical Infectious Diseases, Oxford University Press (OUP), 2018, 66 (10), pp.1588-1594. ⟨10.1093/cid/cix1070⟩
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol 66, iss 10
Clin Infect Dis

Background Minority resistant variants of human immunodeficiency virus type 1 (HIV-1) could influence the virological response to treatment based on nonnucleoside reverse transcriptase inhibitors (NNRTIs). Data on minority rilpivirine-resistant varia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6a84322e05f7b33775ac689589c3c94
https://hal.univ-lorraine.fr/hal-01899957